Thomas Herzog MD
Gynecologic Oncology
Professor of Obstetrics & Gynecology, Columbia P&S
Join to View Full Profile
2139 Auburn AveCincinnati, OH 45219
Phone+1 513-585-2323
Fax+1 513-585-4893
Dr. Herzog is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1990 - 1993
TriHealth (Bethesda North and Good Samaritan Hospitals)Residency, Obstetrics and Gynecology, 1986 - 1990
University of Cincinnati College of MedicineClass of 1986
Certifications & Licensure
OH State Medical License 1988 - 2026
NY State Medical License 2004 - 2015
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- New York Magazine: Top Doctors Castle Connolly, 2007-2014
- Top Doctors: New York Metro Area Castle Connolly, 2007-2013
- Join now to see all
Publications & Presentations
PubMed
- Racial and ethnic enrollment disparities in clinical trials leading to Food and Drug Administration approvals for gynecologic malignancies.Gabriel Levin, Bradley J Monk, Bhavana Pothuri, Robert Coleman, Thomas Herzog
American Journal of Obstetrics and Gynecology. 2025-08-01 - Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.John K Chan, Krishnansu Tewari, Bradley J Monk, Thomas J Herzog, Robert L Coleman
Gynecologic Oncology. 2025-08-01 - The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, Bradley J Monk, Glauco Baiocchi
International Journal of Gynecological Cancer. 2025-06-27
Other
- Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-f
UpToDate, Wolters Kluwer Health - 2012-11-13 - First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ova
UpToDate, Wolters Kluwer Health - 2013-04-08
Press Mentions
Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 7th, 2025- Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 5th, 2025
- Study: Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 4th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
